SCIE期刊信息库

Thank you for choosing to submit your paper to us. These instructions will ensure we have everything required so your paper can move through peer review, production and publication smoothly. Please take the time to read them and follow the instructions as closely as possible.

Should you have any queries, please visit our Author Services website or contact us at authorqueries@tandf.co.uk.

Submit online

Manuscript Submission

Online Submission
OncoImmunology utilizes an online submission and tracking system designed to provide a better, more efficient service to authors.

Authors can submit manuscripts online from anywhere in the world.
Authors can track their manuscript through the peer review process.
Author files are automatically converted into a PDF (Portable Document Format) file and submissions are acknowledged by email.
Editors and reviewers access the PDF files on the website.

Click here to submit your manuscript to OncoImmunology.

Pre-submission Inquiries

Pre-submission inquiries are not necessary but are welcome. These may include either an abstract or a full-length manuscript as an email attachment (Microsoft Word). Pre-submission inquiries should be emailed to the Editor-in-Chief (Laurence Zitvogel; Email: laurence.zitvogel@orange.fr).

Publication Charges

Publication Fee
There is a US$250 publication fee to publish in OncoImmunology. This fee covers the costs of the peer-review process, editing, layout, indexing, and archiving of your article. This fee includes a PDF copy of your article. There are no publication charges for Letters to the Editor, Editorials, and Article Addenda.

For all submissions received on or after October 1, 2015, a page charge will apply at a rate of US$105 per page or partial page.

Under exceptional circumstances, where there are no funds to cover page charges and articles cannot be reduced in size, authors may appeal directly to the Editor for page charges to be waived. This appeal must be supported with a letter signed by a finance official at the author's institution, confirming that no funds are available to cover page charges.

Supplementary File Charges
The following fees apply for any supplementary material posted with a manuscript: A US$100 fee is assessed for all text, figures and/or tables. Supplementary movies carry a rate of US$150 for the first five movie files and US$50 for each subsequent movie file. Fees will be outlined on the publication charge form authors receive with galley proofs.

For all submissions received on or after October 1, 2015, the fees will be as follows: A US$105 fee is assessed for all text, figures and/or tables. Supplementary movies carry a rate of US$155 for the first five movie files and US$53 for each subsequent movie file.

Please provide supplementary material in the following formats:

Text: MS Word file
Table/Data: MS Word file or Excel file
Figures: Please provide figures in a MS Word file or in a PPT file, clearly labeled with figure legends below them.
Video Files: Video submissions for viewing online should be Audio Video Interleave (.avi), MPEG (.mpg, .mp4), or Quick Time (.qt, .mov).
- AVI files can be displayed via Windows Media Player; MPEG files can be displayed via Windows Media Player; Quick Time files require Quick Time software (free) from Apple
- Videos should be brief whenever possible (<2-5 minutes). Longer videos will require longer download times and may have difficulty playing online. Videos should be restricted to the most critical aspects of your research. A longer procedure can be restructured as several shorter videos and submitted in that form.
- It is advisable to compress files to use as little bandwidth as possible and to avoid overly long download times. Video files should be no larger than 5 megabytes. This is a suggested maximum.
- A caption giving a brief overall description of the video content should be provided for each video.
- If your paper is accepted for publication you may wish to supply the editorial office with several different resolutions of your video files. This will allow viewers with slower connections to download a lower resolution version of your video.

Please also provide ALL files in one PDF file. Links to supplementary data will be included in the PDF of the published manuscript and in the online abstract.

Open Access Policy
Taylor & Francis recognizes that an increasing number of research-funding agencies require agency-funded research be deposited in public repositories. It is our mission to help authors comply with their institutions and funding agencies.

Taylor & Francis Open Access License Agreement
All authors will be contacted about Open Access options.

Open Access prices vary based on the type of paper and the desired Creative Commons license you wish to use. A description of the licenses that we work with is here:

CC-BY-NC: Anyone may copy, distribute, transmit, or adapt the work as long as the work is attributed (properly cited). This work may not be used for commercial purposes.
CC-BY: Anyone may copy, distribute, transmit, adapt, or use the work for commercial purposes as long as the work is attributed (properly cited).

Open Access License

Type of Paper

Fee

CC-BY-NC license

Research Paper

Brief Report

Review

Commentary

$750

$500

$250

CC-BY license

Research Paper

Brief Report

Review

Commentary

$1500

$1000

$500

Taylor & Francis Open Access Agreement for CC-BY-NC
Creative Commons Attribution Noncommercial License
Creative Commons Attribution Noncommercial License – Full Legal Code

Taylor & Francis Open Access Agreement for CC-BY
Creative Commons Attribution License
Creative Commons Attribution License – Full Legal Code

If your article type is not reflected in the above table, please contact Customer Service at support@tandfonline.com for pricing.

For all submissions received on or after October 1, 2015, the Open Access fees will be as follows:

Open Access License

Type of Paper

Fee

CC-BY-NC license

Research Paper

Brief Report

Review

Commentary

$785

$525

$265

CC-BY license

Research Paper

Brief Report

Review

Commentary

$1575

$1050

$525

Compliance with Funding Agencies
All manuscripts that are agency-funded (e.g., NIH, HHMI, Wellcome Trust, etc.) and paid for using one of the above Creative Commons licenses will be automatically deposited and made publicly available in PubMed Central by the publisher. Agency-funded articles that are not open access will be deposited by the publisher and publicly available in PubMed Central (and Europe PMC) within 6-12 months of publication. Please note that Wellcome Trust-funded authors selecting an OA option are required by their funder to select the CC-BY license.

MIATA Compliant Manuscript Submission

What Is MIATA Compliance?
The immune monitoring community has recently established a consensus document about the minimal information necessary when reporting results of experiments involving T cells (see the MIATA website for details).

These Minimal Information About T-cell Assays (MIATA) guidelines provide a reporting framework for transparency that allows for an objective and thorough interpretation of published results from T cell-based assays as well as for a superior comparability of results.

The process of providing a guidelines adherent manuscript involves the following:

Write Materials & Method section in MIATA compliant style, which involves providing all required information as outlined in the official guidelines at the the MIATA website. You may use the Supplemental information space for providing requested data, if necessary.
When submitting a MIATA compliant manuscript, you will be required to fill out a checklist (link to PDF) for completeness.

The manuscript will be reviewed for MIATA compliance, and once confirmed, it will receive a MIATA label of compliance, which will be displayed on the manuscript front page. After publication, the MIATA core team will be informed about the paper for listing on the MIATA website and link to the article in OncoImmunology. We encourage that you also inform the MIATA team about your publication ( input@miataproject.org) to accelerate this process.

Why Publish a MIATA-Compliant paper?
The adherence to MIATA guidelines should be regarded as a “label of honor.” This label reflects the following:

“These authors report on their T cell assays transparently and comprehensively as per field-wide consensus, allowing the community a full understanding and interpretation of presented data as well as a comparison of data between groups.”
Secondly, MIATA-adherent manuscripts will be listed at the MIATA homepage. Hence, the label will increase the general awareness and alert more readers to the publication, leading to increased numbers of downloads in the short term and possibly more citations on the long run.

Manuscript Preparation

Types of Papers

Research Papers/Reports
Research Papers or Reports should include the following sections in the following order:

Abstract: A single paragraph of fewer than 250 words. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. References should not be cited in the abstract.
Keywords: Include 5-10 for indexing purposes.
Introduction.
Results: Present results in a logical sequence in tables and illustrations. In the text, explain, emphasize or summarize the most important observations. Units of measurement should be expressed in accordance with Systeme International d'Unites (SI Units).
Discussion: Do not repeat in detail data given in the Results section. Emphasize the new and important aspects of the study. Relate observations to other relevant studies. On the basis of your findings (and others'), discuss possible implications/conclusions. When stating a new hypothesis, clearly label it as such.
Patients and Methods/Materials and Methods: Describe the selection of patients or experimental animals, including controls. Do not use patients' names or hospital numbers. Identify methods, apparatus (manufacturer's name and address) and procedures in sufficient detail to allow other workers to reproduce the results. Provide references and brief descriptions of methods that have been published. When using new methods, evaluate their advantages and limitations. Identify drugs and chemicals, including generic name, dosage and route(s) of administration.
Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.
For reagents listed in the Materials and Methods section, the company that supplied the reagent and the catalog number should be listed in parentheses; do not list the company location.
References: No more than 85.
Figure legends.
Tables: Tables should be numbered consecutively with Arabic numerals and include descriptive titles and legends.

Methods Articles
Methods Articles must present original research that focuses mainly on a new experimental technique, procedure, or reagent that provides a significant advance in the field. These papers should follow the same structure as Research Papers or Short Articles. Please provide an abstract no longer than 100 words.

Brief Reports
Brief Reports should constitute unusually interesting data combined with a discussion of what the data might mean, or an explanation of why the data contradicts current paradigms. The primary goal of the abstract should be to make the general significance and conceptual advance of the work clearly accessible to a broad readership. Please include the following:

Abstract (one paragraph of fewer than 150 words)
5-10 key words for indexing purposes

Reviews
Reviews should be recognized as scholarly by specialists in the field being covered, but should also be written with a view to informing readers who are not specialized in that particular field, and should therefore be presented using simple prose. Please avoid excessive jargon and technical detail. Reviews should capture the broad developments and implications of recent work. The opening paragraph should make clear the general thrust of the review and provide a clear sense of why the review is now particularly appropriate. The concluding paragraph should provide the reader with an idea of how the field may develop or future problems to be overcome, but should not summarize the article.

To ensure that a review is likely to be accessible to as many readers as possible, it may be useful to ask a colleague from another discipline to read the review before submitting it. Submitted reviews are subject to the same page charges as full-length reports. Whether and how page charges will apply for commissioned reviews will be made clear when each review is commissioned.

Reviews should be up to 4,000 words and include an abstract of up to 100 words, a maximum of 4 figures/tables, and up to 80 references.

Author's View
An "Author's View" is a short piece that allows authors to describe a recent research paper from their lab published elsewhere. Please limit the paper to 900 words with a 50 word (approx) abstract. You may include up to 10 references and 1 figure. Please do not include any acknowledgements.

Author's Views will be invited by the Editors-in-Chief.

Points-of-View
Point-of-View articles should follow the same general guidelines as Reviews; however, there is considerable flexibility in their structure and content. These articles are intended to address controversial issues, express new ideas, or expand on work already published. They may contain new data, and like other submissions, are subject to peer review. Like Review articles, they should be accessible to a wide readership.

Point-of-View articles are generally commissioned from authors of the most important recent papers to offer additional insights. Unsolicited Point-of-View articles are also welcome, and these may discuss the authors' own work and/or recent significant advances in their field. Points-of-View may be up to 2,500 words and should also include an abstract of up to 50 words. They may include up to 2 figures/tables and no more than 30 references.

Responses to Point-of-View articles are encouraged and will also be published as Point-of-View articles. Responses may be considerably shorter and structured as letters.

Previously Submitted
OncoImmunology recognizes that excellent papers may have been erroneously rejected by other journals. We will reconsider papers that have been rejected by Nature, Science, Nature Medicine, Nature Cell Biology, Cell, Cancer Cell, Cell Metabolism, Developmental Cell, NEJM, Lancet, Genes & Development and some other journals in the original format of those journals, thus saving the authors effort and time. Authors are encouraged to enclose the reviewers' and/or editorial comments from the journals mentioned above. This will expedite the evaluation of the article. In some instances, the article may be accepted based on the previous review. This allows urgent and competitive research to be published soon after submission. Papers submitted using the Select Submission Track can be accepted within 1-2 days.

Please submit your paper and contact the Editor-in-Chief with the manuscript number and a PDF with the previous review. Upon acceptance, authors should provide the paper in OncoImmunology's format.

Organization

All manuscripts should be in English. Please ensure that manuscripts are clear, concise and grammatically correct.

Non-Native Speakers of English
Authors who are not native speakers of English and submit manuscripts to international journals, often receive negative comments from referees or editors about English-language usage. These problems can contribute to a decision to reject a paper. To help reduce the possibility of such problems, we strongly encourage such authors to take at least one or both of the following steps:

Have your manuscript reviewed for clarity by a colleague whose native language is English.
Use a service such as one of those listed at the end of our guidelines. An editor will improve the English to ensure that your meaning is clear and identify problems that require your review. Note that the use of such a service is at the author's own expense and risk, and does not guarantee that the article will be accepted. Taylor & Francis accepts no responsibility for the interaction between the author and the service provider or for the quality of the work performed.

Text should be prepared in MS Word, double-spaced, with page numbers throughout and line numbering turned on. Click here for directions on adding line numbers.

Organize manuscripts in the following manner:

Title page, including titles, author's names (first, MI, last) and affiliations
5-10 keywords (for indexing purposes)
A list of abbreviations and acronyms used throughout the text
An abstract (please see Type of Paper for word limit), the primary goal of which is to make the general significance and conceptual advance of the work clearly accessible to a broad readership. (References should not be cited in the abstract.)
Text (length and organization depends upon type of paper)
Acknowledgments
References
Figure legends
Tables (with descriptive titles and legends)

There are no word limits for papers published, however, accepted manuscripts are published with the understanding that page charges will be assessed.

If your paper is to be published in a journal indexed by PubMed/Medline, the citation of your article will be sent to PubMed within one week of acceptance; therefore, please ensure that all information is correct.

Text Files/Tables
Please save text and table files as MS Word documents. Figure legends should be at the end of the manuscript following references. Tables will be reformatted during production and therefore should only be minimally formatted in your text file and follow the figure legends.

Figure Preparation
Figures should be as small and simple as clarity permits. Unnecessary figures and panels in figures should be avoided: data presented in small tables or histograms, for instance, can generally be stated briefly in the text instead. Avoid unnecessary complexity, coloring and excessive detail. Figures should not contain more than one panel unless the parts are logically connected. Where possible, text, including keys to symbols, should be provided in the text of the figure legend rather than on the figure itself. Any image processing should be explained clearly in the Materials and Methods section of your manuscript.

To aid in the processing and turnaround of issues, we ask that authors please adhere to the following figure guidelines. Authors will be asked to revise details and images if they do not adhere to the figure protocols.

Guidelines for Figure Preparation
Image presentation
(These guidelines for image presentation are adapted from the “Instructions for Authors” that are posted on the Journal of Cell Biology web site, and are included here with permission).

As you prepare your figures, please adhere to the following guidelines to accurately present your data:

No specific feature within an image may be enhanced, obscured, moved, removed, or introduced.
The grouping of images from different parts of the same gel, or from different gels, fields, or exposures must be made explicit by the arrangement of the figure (i.e., using dividing lines) and in the text of the figure legend.
Adjustments of brightness, contrast, or color balance are acceptable if they are applied to the whole image and as long as they do not obscure, eliminate, or misrepresent any information present in the original, including the background. Non-linear adjustments must be disclosed in the figure legend.

A more detailed discussion of image presentation can be found at the following URL: http://jcb.rupress.org/content/166/1/11.full (Rossner and Yamada, J. Cell Biol. 166:11–15)

Resolution
All submitted images must be of high quality and have resolutions of 300 dpi ready for print.

Formats
We require figures in electronic format. Please do not send PowerPoint, MS Word, presentation or paint files as they are inadequate for the creation of high quality images. Much of the information contained in PowerPoint or other file types is lost or skewed in the conversion of images. Figures should be provided as TIF, Photoshop, EPS or high resolution PDF files. Compatible graphic art programs are Adobe Illustrator and Adobe Photoshop.

Figure size
Figures should be submitted at the size they are to be published. Maximum width = 7.1 in. Maximum height = 9.5 in.

For multi-panel figures (such as figure 1a, 1b, 1c, etc.), each panel should be assembled into one image file. Do not include separate panels on multiple pages, i.e. A, B, C and D should all fit on one page. Each panel should be sized so that the figure as a whole can be reduced by the same amount and reproduced on the printed page at the smallest size at which essential details, including type, are visible and readable.

Color mode
Save all color figures in CMYK mode at 8 bits/channel. Layering type directly over shaded or textured areas and using reversed type (white lettering on a colored background) should be avoided.

Type
Please be sure to embed all fonts. Use a sans serif font such as Helvetica. The font size should be no greater than 9 pt. and no smaller than 6 pt; however, panel labels (A, B, C) should be 15 pt. uppercase (not bold). Lettering in figures (labeling of axes and so on) should be in lowercase type, with the first letter capitalized and no full stop. Please keep font size relatively the same throughout the figures so as to avoid scaling issues. Also note that readability suffers if type is layered over a pattern or color other than white or black.

Units
Units should have a single space between the number and the unit, and follow SI nomenclature or the nomenclature common to a particular field. Thousands should be separated by commas (1,000). Unusual units or abbreviations should be defined in the legend. Please use the proper microsymbol (denoting a factor of one millionth) rather than a lower case u.

References
Include in the reference list only those articles that have been published or have been accepted for publication. All references to unpublished data or personal communications must be cited within the text.

Use the citation-sequence system: The list of references should be numbered consecutively according to the sequence of first appearance within the article text. For in-text references, use only the number assigned to the reference:

Correct: according to Jones. ¹
Incorrect: according to Jones ¹.
Correct: noted by Smith et al. ¹
Incorrect: Smith et al (1).

When referring the reader to specific references as part of a sentence please use the following format:

Correct: For a review see refs. 20-25.
Incorrect: For a review see 20-25

Journal References

The reference format is the same for all of our journals. You may download the output style for Cell Cycle from Endnotes, or view it in the CSL Style Repository.
List, at minimum, ten author names before using “et al.”
Abbreviate journal names according to the style used in Index Medicus or a comparable source and omit punctuation after journal titles. Spell out foreign or less commonly known journal names.

Standard format:
[Author's last name] [Author's initials], [First ten author's last names followed by their initials]. [Title of article with only the first word capitalized]. [Journal's standard abbreviated name] [Year]; [Volume]:[Inclusive pages].

For Example:
Haegel H, Thioudellet C, Hallet R, Geist M, Menguy T, Le Pogam F, Marchand J, Toh M, Duong V, Calcei A, et al. A unique anti-CD115 monoclonal antibody which inhibits osteolysis and skews human monocyte differentiation from M2-polarized macrophages toward dendritic cells. mAbs 2013; 5: 243–56.

Other Types of References
For all other types of reference styling formats, please refer to the National Library of Medicine Style Guide for Authors, Editors and Publishers which is available here: http://www.ncbi.nlm.nih.gov/books/NBK7256

Featured Image Submission
OncoImmunology selects a featured illustration from accepted articles and from submitted images that are designed to accompany an accepted article.

The illustration should be scientifically interesting and visually attractive. It need not be a figure from the paper, but should be closely related to the subject of the paper. If you are interested in submitting a figure for use as a featured image in OncoImmunology, please email a high-resolution version of your image, conforming to the specifications below, and an explanatory caption of 50-60 words to the Managing Editor.

All potential images should be sized to fit on a single letter size (8.5" x 11") page. Please remove all text, captions, etc. from the image. If you have variations of the image, you may send additional files. Please send no more than two alternate versions.

Accepted formats and resolution:

PSD (Adobe Photoshop: if graphics are built with layers, do not flatten), 300 dpi, CMYK at 100% size.
TIF, 300 dpi, CMYK at 100% size
JPG, 300 dpi highest quality, CMYK at 100% size.
EPS (scalable vector line art)
AI (Adobe Illustrator)

Page Proofs
Page proofs will be sent to the author via email. Page proofs should be returned within two working days, preferably by email. Corrections should be marked on the actual proof and provided in a numbered list. Lengthy additions should be avoided, but where necessary should be provided in a MS Word file, with explicit instructions regarding placement.

Policies

Editorial Policies
When a manuscript is submitted, the Editors assume that no similar paper has been or will be submitted for publication elsewhere. Further, it is understood that all authors listed on a manuscript have agreed to its submission.

Upon acceptance, authors must sign an author agreement with the publisher granting exclusive license to publish. Should the authors choose to make their paper freely available, then Open Access options are available with CC-BY-NC or CC-BY license.

Manuscripts should conform to the Uniform Requirements for Manuscripts Submitted to Biomedical Journals (URMSBJ), which can be found in full at www.icmje.org. This is in addition to their need to conform to our general guidelines about layout, etc. In particular, the attention of authors is drawn to the following conditions (which are extracted from the URMSBJ):

Authorship (Informed Consent)
Authorship credit should be based on 1) substantial contributions to conception and design, acquisition of data or analysis and interpretation of data; 2) drafting the article or reviewing/revising it critically for important intellectual content and 3) final approval of the version to be published. Each author should meet all three of these criteria. Acquisition of funding, or general supervision of a research group, are not valid criteria for authorship. Individuals who have a lesser involvement should be thanked in the acknowledgements. If meeting these requirements causes problems for a particular manuscript, authors are encouraged to contact the Editor-in-Chief for advice on alternative ways other contributors can be listed.

Acknowledgment of Funding
Authors should list all sources of funding for the research described in a manuscript in the 'Acknowledgments' section.

Conflict of Interest
Potential conflicts of interest exist when an author or reviewer has financial or personal interests in a publication that might, in principle, influence their scientific judgment. Financial interests include, but are not limited to, stock-holding, consultancy, paid expert testimony and honoraria; they also include any limitations on freedom to publish that are imposed on an author by an employer or funding agency. In order to encourage transparency without impeding publication, authors are required to include a statement at the end of a manuscript that lists all potential financial interests or, if appropriate, that clearly states that there are none. Possible conflicts of interest of a personal nature should also be communicated to the Editor-in-Chief, who will discuss with the author whether these ought to be listed. Peer reviewers are also required to inform the Editor-in-Chief of any potential conflicts of interest, financial or otherwise.

Ethical Statements
If a study involves any ethical issues, which include patient confidentiality and treatment of animals, the paper must be accompanied by a statement to the effect that the authors complied with all of the legal requirements pertaining to the location(s) in which the work was done. Indicate whether the procedures were approved by the Ethics Committee of Human Experimentation in your country, or are in accordance with the Helsinki Declaration of 1975.

Publishing Ethics
The Editors and Taylor & Francis Group are committed to the highest academic, professional, legal, and ethical standards in publishing work in this journal. To this end, we have adopted a set of guidelines, to which all submitting authors are expected to adhere, to assure integrity and ethical publishing for authors, reviewers, and editors.

Taylor & Francis is a member of the Committee of Publications Ethics (COPE). COPE aims to provide a forum for publishers and editors of scientific journals to discuss issues relating to the integrity of their work, including conflicts of interest, falsification and fabrication of data, plagiarism, unethical experimentation, inadequate subject consent, and authorship disputes. For more information on COPE please visit http://publicationethics.org.

Duplicate or Redundant Publication

We only publish original manuscripts that are not also published or going to be published elsewhere. Duplicate publications, or redundant publications (re-packaging in different words of data already published by the same authors) will be rejected. If detected after publication, the Editor reserves the right to publish a notice of the fact without requiring the authors' approval. Competing manuscripts on the same study, for example by collaborators who have split into rival teams after the data were gathered, are acceptable only under special circumstances: please contact the Editor-in-Chief for advice.

Plagiarism and Other Fraud
If the Editor has reason to suspect that a manuscript is plagiarized or fraudulent, he or she reserves the right to bring his concerns to the authors' sponsoring institution and any other relevant bodies. Upon submission, all manuscripts go through a rigorous quality control check that includes evaluation by iThenticate to identify any previously published phrases. Authors should pay particular attention to the originality of their work.

Limits to Freedom of Expression
We are committed to academic freedom. It does, however, have to operate within the laws of the USA, where it is published. Although a liberal democracy that is committed to academic freedom, it does have certain legal restrictions on the publication of specific types of material (for example, defamation of character, incitement to racial hatred, material intended to aid terrorism, etc.). In the unlikely event that a manuscript contains material that contravenes these restrictions, the journal reserves the right to request that the material is removed from the manuscript or that the manuscript is withdrawn. In any case, the journal requires authors to take full legal responsibility for what they have written.

Availability of Materials and Data
It is expected that authors should be able to provide any materials and/or protocols used in published experiments to other qualified researchers for their own use. Materials include (but are not limited to): cells DNA, antibodies, reagents, organisms, mouse strains, and Drosophila strains. These should be made available in a timely manner and it is acceptable to request reasonable payment to cover the cost of maintenance and transport.

For materials such as mutant strains and cell lines, authors should use established public repositories and provide relevant accession numbers wherever possible.

Repositories include:

Jackson Laboratory (mouse strains)
Bloomington Drosophila Stock Center at Indiana University (fly strains)
Drosophila Genomics Resource Center (DNA clones and cell lines)
MMRRC (Mutant Mouse Regional Resource Centers)
UK Stem Cell Bank

Papers reporting protein or DNA sequences and molecular structures should provide an accession number to any of the three major collaborative databases: DDBJ, EMBL or GenBank. It is only necessary to submit to one database as data are exchanged between DDBJ, EMBL and GenBank on a daily basis. The suggested wording for referring to accession-number information is: "These sequence data have been submitted to the DDBJ/EMBL/GenBank databases under accession number U12345."

ORCID
ORCID is an open, non-profit, community-driven effort to create and maintain a registry of unique researcher identifiers and a transparent method of linking research activities and outputs to these identifiers. Authors are encouraged to provide an ORCID for themselves and coauthors.

For more information about ORCID, please visit: orcid.org.

Peer Review
Each contribution is typically vetted by at least two expert reviewers who are either members of the Editorial Board or are recruited by Board members.

For original articles or short reports, reviewers will generally be asked to comment on the following aspects of the submitted manuscripts:

significance to the field
study of data
quality of data
quality of controls
whether conclusions are justified
whether the effects are meaningful
whether the study is described clearly
the novelty of the work

If the reviewers believe the paper is potentially acceptable, but could be improved, specific suggestions will be made for improvement.

Final acceptance of all submitted manuscripts is a decision made by the Editor(s) in consultation with the Editorial Board and reviewers. If a manuscript does not meet the standards of the journal or is otherwise lacking in scientific rigor or contains major deficiencies, the reviewers will attempt to provide constructive criticism to assist the authors in ultimately improving their work for publication, here or elsewhere. Manuscripts not invited for resubmission will not be reconsidered.

If a manuscript receives favorable reviews but is not accepted outright following the initial review, it may be invited for reconsideration with the expectation that the authors will fully address the reviewer’s criticisms. Resubmitted manuscripts with major revisions will be sent back for peer review.

Accepted papers will be posted in their accepted form to Taylor & Francis online. They will be clearly labelled as the Author’s Accepted Manuscript (AAM), and later replaced by the Version of Record (VoR).

Author Self-Archiving
Authors are entitled to deposit the AAM in their institution's repository, subject to Taylor & Francis’ policy on such deposits (see “Sharing Your Work”). We require that a link to the published version at the journal's website is included, along with attribution to the journal as the original source (with full citation details).

Corrections and Retractions

All formal notices of correction, retraction, and expressions of concern are published as separate article entries that contain citation information and/or directly link back to the original publication to which they apply. If a title is published in print, the notification will also be included in the corresponding print version of a journal.

Corrections
Corrections should be brought to the attention of the Production Editor and/or Editor-in-Chief of the specific journal title for resolution. Significant errors that may impact the understanding of the science or incorrect elements that may effect the citation of the publication (i.e., misspelling of an author’s name) are grounds for formal correction. These include significant errors resulting from mistakes introduced by publishing staff during the production and editing process of an article or notification of errors in scientific logic, methodology and/or omissions by authorship. Note, a formal correction will not be published for basic grammatical or typographical errors.

Retractions and Expressions of Concern
If the integrity of a publication is brought into question, concerns should be brought to the attention of the Editor-in-Chief.

In the unlikely event that potential error in scientific logic or methodology invalidates the results of an entire body of work, a partial or full retraction of the article, may be published. In these instances, were authors voluntarily elect to retract their own work, circumstances are addressed between the authorship and Editor-in-Chief.

Retraction of an article may also be issued on confirmed instances of scientific fraud related to plagiarism, fraudulent data usage, invalid claims of authorship, or breaches in professional codes of ethics. If the grounds for retraction are confirmed by the author(s) institution(s) or funding agency related to the work, a formal retraction will be published. If an investigation into scientific fraud does not reach a satisfactory conclusion and validity remains uncertain or if the investigation appears to be drawn out over an extended period of time (without a foreseen date of closure), an “Expression of Concern” regarding the validity of the original publication may be published.

General Reader Feedback and Criticisms
Readers are encouraged to submit feedback to the Editor-in-Chief that supports,challenges, and/or elaborates upon previous publications. The Editor-in-Chief may consult with the original authorship of a publication or seek the advice of peer-reviewers to determine an appropriate response in cases where significant errors are noted.

If the feedback is of significant interest, it may be considered for publication as a “Letter to the Editor” at the discretion of the Editor-in-Chief. In these cases, the original authorship of a publication may be given the chance to respond to the feedback in a published “Reply to” or “Response to” article.

Aims & scope

MIATA Compliance

Subjects covered by this journal

Abstracting & indexing